Global Systemic Scleroderma Drugs Market Research Report 2023

Publication ID:

PB504237208

Publication Date:

May 16, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Systemic scleroderma听is an autoimmune disorder that affects the skin and internal organs . It is characterized by the buildup of scar tissue (fibrosis) in the skin and other organs. The fibrosis is caused by the body's production of too much collagen, which normally strengthens and supports connective tissues.
Highlights
The global Systemic Scleroderma Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Systemic Scleroderma Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Systemic Scleroderma Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Systemic Scleroderma Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Systemic Scleroderma Drugs include Boehringer Ingelheim International GmbH, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc. and Bayer AG, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Systemic Scleroderma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Scleroderma Drugs.
The Systemic Scleroderma Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Systemic Scleroderma Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Systemic Scleroderma Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Boehringer Ingelheim International GmbH
Gilead Sciences Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Bayer AG
Segment by Type
Immunosuppressors
Phosphodiesterase 5 inhibitors - PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Others
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Systemic Scleroderma Drugs companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Systemic Scleroderma Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immunosuppressors
1.2.3 Phosphodiesterase 5 inhibitors - PHA
1.2.4 Endothelin Receptor Antagonists
1.2.5 Prostacyclin Analogues
1.2.6 Calcium Channel Blockers
1.2.7 Others
1.3 Market by Application
1.3.1 Global Systemic Scleroderma Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Systemic Scleroderma Drugs Market Perspective (2018-2029)
2.2 Systemic Scleroderma Drugs Growth Trends by Region
2.2.1 Global Systemic Scleroderma Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Systemic Scleroderma Drugs Historic Market Size by Region (2018-2023)
2.2.3 Systemic Scleroderma Drugs Forecasted Market Size by Region (2024-2029)
2.3 Systemic Scleroderma Drugs Market Dynamics
2.3.1 Systemic Scleroderma Drugs Industry Trends
2.3.2 Systemic Scleroderma Drugs Market Drivers
2.3.3 Systemic Scleroderma Drugs Market Challenges
2.3.4 Systemic Scleroderma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Systemic Scleroderma Drugs Players by Revenue
3.1.1 Global Top Systemic Scleroderma Drugs Players by Revenue (2018-2023)
3.1.2 Global Systemic Scleroderma Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Systemic Scleroderma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Systemic Scleroderma Drugs Revenue
3.4 Global Systemic Scleroderma Drugs Market Concentration Ratio
3.4.1 Global Systemic Scleroderma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Systemic Scleroderma Drugs Revenue in 2022
3.5 Systemic Scleroderma Drugs Key Players Head office and Area Served
3.6 Key Players Systemic Scleroderma Drugs Product Solution and Service
3.7 Date of Enter into Systemic Scleroderma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Systemic Scleroderma Drugs Breakdown Data by Type
4.1 Global Systemic Scleroderma Drugs Historic Market Size by Type (2018-2023)
4.2 Global Systemic Scleroderma Drugs Forecasted Market Size by Type (2024-2029)
5 Systemic Scleroderma Drugs Breakdown Data by Application
5.1 Global Systemic Scleroderma Drugs Historic Market Size by Application (2018-2023)
5.2 Global Systemic Scleroderma Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Systemic Scleroderma Drugs Market Size (2018-2029)
6.2 North America Systemic Scleroderma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Systemic Scleroderma Drugs Market Size by Country (2018-2023)
6.4 North America Systemic Scleroderma Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Systemic Scleroderma Drugs Market Size (2018-2029)
7.2 Europe Systemic Scleroderma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Systemic Scleroderma Drugs Market Size by Country (2018-2023)
7.4 Europe Systemic Scleroderma Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Systemic Scleroderma Drugs Market Size (2018-2029)
8.2 Asia-Pacific Systemic Scleroderma Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Systemic Scleroderma Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Systemic Scleroderma Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Systemic Scleroderma Drugs Market Size (2018-2029)
9.2 Latin America Systemic Scleroderma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Systemic Scleroderma Drugs Market Size by Country (2018-2023)
9.4 Latin America Systemic Scleroderma Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Systemic Scleroderma Drugs Market Size (2018-2029)
10.2 Middle East & Africa Systemic Scleroderma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Systemic Scleroderma Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Systemic Scleroderma Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim International GmbH
11.1.1 Boehringer Ingelheim International GmbH Company Detail
11.1.2 Boehringer Ingelheim International GmbH Business Overview
11.1.3 Boehringer Ingelheim International GmbH Systemic Scleroderma Drugs Introduction
11.1.4 Boehringer Ingelheim International GmbH Revenue in Systemic Scleroderma Drugs Business (2018-2023)
11.1.5 Boehringer Ingelheim International GmbH Recent Development
11.2 Gilead Sciences Inc.
11.2.1 Gilead Sciences Inc. Company Detail
11.2.2 Gilead Sciences Inc. Business Overview
11.2.3 Gilead Sciences Inc. Systemic Scleroderma Drugs Introduction
11.2.4 Gilead Sciences Inc. Revenue in Systemic Scleroderma Drugs Business (2018-2023)
11.2.5 Gilead Sciences Inc. Recent Development
11.3 GlaxoSmithKline plc
11.3.1 GlaxoSmithKline plc Company Detail
11.3.2 GlaxoSmithKline plc Business Overview
11.3.3 GlaxoSmithKline plc Systemic Scleroderma Drugs Introduction
11.3.4 GlaxoSmithKline plc Revenue in Systemic Scleroderma Drugs Business (2018-2023)
11.3.5 GlaxoSmithKline plc Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Systemic Scleroderma Drugs Introduction
11.4.4 Novartis AG Revenue in Systemic Scleroderma Drugs Business (2018-2023)
11.4.5 Novartis AG Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Detail
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Systemic Scleroderma Drugs Introduction
11.5.4 Pfizer Inc. Revenue in Systemic Scleroderma Drugs Business (2018-2023)
11.5.5 Pfizer Inc. Recent Development
11.6 Bayer AG
11.6.1 Bayer AG Company Detail
11.6.2 Bayer AG Business Overview
11.6.3 Bayer AG Systemic Scleroderma Drugs Introduction
11.6.4 Bayer AG Revenue in Systemic Scleroderma Drugs Business (2018-2023)
11.6.5 Bayer AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Boehringer Ingelheim International GmbH
Gilead Sciences Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Bayer AG

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂